Develops and markets hemoadsorption technology based on biocompatible polymer beads for blood purification in intensive care medicine.
CytoSorbents Corporation
Princeton, New Jersey, USA · Berlin, GermanyNew on Amplifa
About CytoSorbents
CytoSorbents Corporation is a publicly listed medical technology company (NASDAQ: CTSO) headquartered in Princeton, New Jersey, with a European subsidiary, CytoSorbents Europe GmbH, in Berlin. The company develops and markets blood purification solutions based on proprietary polymer bead technology for extracorporeal hemoadsorption. The highly porous, biocompatible beads (ISO 10993 certified) adsorb hydrophobic substances such as cytokines, bilirubin, myoglobin as well as the antithrombotic drugs ticagrelor and rivaroxaban from whole blood. The product portfolio includes the CytoSorb adsorber (CE-approved since 2011), the PuriFi platform for standalone CytoSorb therapy (CE marking under MDR since 06/2024), the ECOS-300CY adsorber for ex-vivo organ perfusion, and VetResQ for veterinary medicine. The products are sold in more than 75 countries on six continents through distributors such as Fresenius Medical Care; an OEM partnership exists with Aferetica. A global team of more than 150 professionals supports physicians with training and 24/7 support.
- Site
- Berlin
- Processes
- Training & Education (training courses, setup videos, CME continuing education), 24/7 Support & Expertise on Demand, Customized Training & Support Materials, Medical Information, Sales through distributors worldwide
- Materials
- Highly porous biocompatible polymer beads (bead technology)
- Certificates
- ISO 10993 (biocompatibility of the bead technology), CE marking (CytoSorb, PuriFi, ECOS-300CY), ISO 10993 (biocompatibility), CE marking / MDR
- Employees
- 150+
- Industries
- Medical technology, Intensive care / Critical Care, Cardiac surgery / Cardiovascular, Transplantation medicine (ex vivo organ perfusion), Nephrology, Hepatology
- 01
Research & development of the polymer bead technology
- 02
Manufacturing of the adsorption products (CytoSorb, PuriFi, ECOS-300CY)
- 03
Regulatory approval (CE marking/MDR)
- 04
Sales through distributors worldwide
- 05
Training, education & 24/7 support for users
Technology & Materials
Highly porous biocompatible polymer beads (bead technology)
The basis of all CytoSorbents products; ISO 10993 certified for biocompatibility and hemocompatibility, adsorbs hydrophobic molecules up to approx. 60 kDa from whole blood.
Locations
Princeton, New Jersey
USHeadquarters (CytoSorbents Corporation & CytoSorbents Medical Inc.)
Berlin
DEEuropean subsidiary (CytoSorbents Europe GmbH)
Products & Solutions
Inside the production
Industries
Additional services
Reference customers
Quality
The bead technology is certified to ISO 10993 for biocompatibility and hemocompatibility. CytoSorb, PuriFi and ECOS-300CY are CE marked (PuriFi under MDR since 06/2024).
| Evidence | Princeton, New Jersey | Berlin |
|---|---|---|
| ISO 10993 (biocompatibility) | ||
| CE marking / MDR |
History
- 2011
CytoSorb received CE approval
- 2020
Dr. Efthymios Deliargyris joined as Chief Medical Officer
- 2022
Daniel Wendt joined as VP Medical Cardio-Vascular
- 2024
PuriFi received CE marking under MDR (06/2024)